Drug Trial Radar · NCT06416865
Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
193
Actual
Start
Oct 18, 2022
Primary completion
Dec 23, 2024
Study completion Feb 19, 2025
Sponsor
- Lead sponsor
- AJU Pharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Double-blind, Multi-center, Phase III study to evaluate the efficacy and safety of the AJU-C52 compared with the combination of C52R1M in patients with essential Hypertension Patients who have inappropriately controlled on C52R1L treament
Conditions
- Essential Hypertension
Interventions
AJU-C52L, AJU-C52Drug
AJU-C52L+C52R1L placebo: Subjects take the investigational products once a day for 2 weeks. AJU-C52+C52R1M placebo: Subjects take the investigational products once a day for 6 weeks.
C52R1L, C52R1MDrug
C52R1L+AJU-C52L placebo: Subjects take the investigational products once a day for 2 weeks. C52R1M+AJU-C52 placebo: Subjects take the investigational products once a day for 6 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in MSSBP(mean sitting systolic blood pressure)Time frame: 8th week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
AJU Pharm Co., Ltd.
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.